Provided by Tiger Fintech (Singapore) Pte. Ltd.

iTeos Therapeutics

10.17
0.0000
Volume:382.74K
Turnover:3.88M
Market Cap:389.24M
PE:-3.29
High:10.20
Open:10.10
Low:10.06
Close:10.17
Loading ...

EcoR1 Capital, LLC Reports Acquisition of Common Shares of Iteos Therapeutics Inc

Reuters
·
17 May

Ansbert Gadicke Reports Disposal of Common Shares of Iteos Therapeutics Inc

Reuters
·
16 May

Beneficial Owner MPM BioVentures 2014, L.P. Reports Disposal of Common Shares of Iteos Therapeutics Inc

Reuters
·
16 May

iTeos Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
15 May

iTeos Therapeutics Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
14 May

HC Wainwright Downgrades iTeos Therapeutics to Neutral From Buy

MT Newswires Live
·
14 May

Iteos Therapeutics Inc : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $9 From $47

THOMSON REUTERS
·
14 May

iTeos Therapeutics (ITOS) Receives a Buy from Piper Sandler

TIPRANKS
·
14 May

iTeos Therapeutics price target lowered to $13 from $16 at Wells Fargo

TIPRANKS
·
14 May

U.S. RESEARCH ROUNDUP-Fair Issac, First Solar, UnitedHealth

Reuters
·
14 May

Iteos Therapeutics Inc : JP Morgan Cuts to Neutral From Overweight; Cuts Target Price to $8 From $15

THOMSON REUTERS
·
14 May

Iteos Therapeutics Inc. Files Initial Statement of Beneficial Ownership; EcoR1 Capital, LLC Named as Beneficial Owner

Reuters
·
14 May

iTeos Therapeutics Cut to Neutral From Overweight by JP Morgan

Dow Jones
·
14 May

BUZZ-iTeos rises as it looks to conserve cash after cancer drug setback

Reuters
·
14 May

ITeos Therapeutics Shares Gain as Company Seeks Strategic Alternatives

Dow Jones
·
14 May

iTeos Therapeutics downgraded to Neutral at JPMorgan after TIGIT program ended

TIPRANKS
·
14 May

iTeos Therapeutics downgraded to Neutral from Overweight at JPMorgan

TIPRANKS
·
14 May

British stocks mixed as investors assess US inflation, UK labour market report

Reuters
·
14 May

iTeos Therapeutics Up Over 17%, on Pace for Largest Percent Increase in Over a Year -- Data Talk

Dow Jones
·
13 May

Wedbush Adjusts Price Target on iTeos Therapeutics to $10 From $25, Maintains Outperform Rating

MT Newswires Live
·
13 May